Ovagen Preclinical

What It Is

Ovagen is a synthetic ultrashort peptide with the sequence Glu-Asp-Leu (EDL) — three amino acids, molecular formula C₁₅H₂₅N₃O₈, molecular weight 375.37 Da. It belongs to the Khavinson peptide bioregulator family developed across four decades of work by Professor Vladimir Khavinson and collaborators at the St Petersburg Institute of Bioregulation and Gerontology (IBG) and the D.O. Ott Research Institute of Obstetrics, Gynecology, and Reproductology (Russian Academy of Sciences).

The Khavinson program began in the 1970s with crude peptide extracts from animal organs (thymus, pineal, prostate, retina, etc.) that produced what the Russian literature describes as tissue-specific "bioregulatory" effects — modulation of tissue function that tracks with the origin organ of the extract. Over time, these complex extracts were fractionated and the active peptides identified as short (di- to tetra-peptide) sequences. The Khavinson group then synthesized the corresponding ultrashort peptides and reproduced the tissue-specific bioregulatory effects, producing the named synthetic peptide bioregulators: Epithalon (AEDG, pineal / telomere), Cortexin / Pinealon / Testagen / Livagen / Vesugen / Ovagen / Vilon / Prostamax and others, each with claimed tissue-specific activity matching the organ from which the original extract was derived.

Ovagen (EDL) is positioned in this lineage as a hepato-gastrointestinal tissue-associated peptide, with research interest focused on hepatoprotection, gastrointestinal epithelial function, and related tissue-specific transcriptional signatures. The nomenclature is a historical artifact of the Russian development program and does not denote ovarian targeting — the adjacent named Khavinson peptide for ovarian tissue is Ovaramin (an ovarian complex) / Zhenoluten (A-15), not Ovagen.

A notable disambiguation: a separate Russian-registered veterinary pharmaceutical also named "Ovagen" consists of ovine (sheep) follicle-stimulating hormone used for superovulation in breeding applications. That product is distinct from the Khavinson tripeptide on this page and shares only the trade-name phonetics. The Kalios profile refers exclusively to Khavinson's Glu-Asp-Leu tripeptide.

Mechanism of Action

• Intranuclear peptide-DNA interaction (Khavinson hypothesis) — The defining mechanistic claim of the Khavinson bioregulator family is that ultrashort peptides penetrate into the cell nucleus and engage directly with chromatin / DNA to modulate gene expression. The proposed interactions include sequence-specific binding to promoter regions and modulation of chromatin decondensation. This mechanism is unusual — most therapeutic peptides act at cell-surface receptors — and not universally accepted in the broader peptide-pharmacology literature.
• POT-family transporter uptake — Ovagen and related tripeptides are substrates for the POT (proton-dependent oligopeptide transporter) family — PEPT1 (SLC15A1) and PEPT2 (SLC15A2) — which are the same transporters responsible for di/tripeptide absorption in the small intestine and for renal tubular reabsorption. Uptake through these transporters is biophysically well-characterized; it is the downstream intranuclear mechanism that remains preliminary.
• Tissue-specific gene expression modulation (claimed) — The Khavinson literature describes Ovagen-induced changes in hepatic and GI-epithelial gene expression signatures relevant to detoxification, bile acid metabolism, epithelial regeneration, and antioxidant defense. These claims are primarily Russian-language and supported by in vitro chromatin-interaction studies and animal histology.
• Hepatoprotection (preclinical) — Animal models of chemical liver injury (carbon tetrachloride, paracetamol / acetaminophen) show reduced transaminase elevations and improved liver histology with Ovagen pretreatment.
• GI epithelial barrier support (preclinical) — Rodent models report Ovagen effects on tight-junction protein expression and mucosal integrity, though this data is thinly published relative to the hepatic claims.
• Anti-inflammatory gene-expression signature — Khavinson literature proposes Ovagen dampens hepatic and intestinal pro-inflammatory gene expression, consistent with the broader Khavinson bioregulator family claim of anti-inflammatory effect.
• Regenerative / proliferative support — Proposed stimulation of hepatocyte and GI epithelial cell proliferation after toxic or inflammatory damage.
• mTOR / autophagy considerations — Recent review literature speculates on mTOR-pathway engagement of EDL and related tripeptides; mechanism is preliminary.
• Not a receptor agonist in conventional terms — Ovagen does not activate any known cell-surface receptor for which it is a canonical ligand; the mechanism is proposed to be transcriptional, not GPCR-mediated.
• Comparative Khavinson family mechanism — Ovagen shares the proposed intranuclear / gene-expression-modulation mechanism with the rest of the Khavinson ultrashort peptide family (Epithalon AEDG, Pinealon EDR, Vesugen KED, Livagen KEDA, Testagen KEDG). C-terminal residue variation is hypothesized to drive tissue-specific targeting within this shared framework.
• Oral bioavailability feasibility — Ultrashort (di / tri / tetrapeptide) length supports oral absorption through PEPT1 / PEPT2 transporter pathways — the same transporters that mediate absorption of dipeptide-derived pharmaceuticals (e.g., cefadroxil). Oral Khavinson peptide products lean on this established transporter biology.
• Proteolytic stability considerations — Ultrashort peptides are more stable against proteolytic degradation than longer peptides because they lack many of the cleavage recognition sequences targeted by major gut and plasma proteases. This supports oral administration at room-temperature-stable capsule form.
• Sequence-specific DNA binding (proposed) — The Khavinson hypothesis includes sequence-specific peptide-DNA interactions in promoter regions of target genes. Biophysical studies from the group describe peptide-DNA binding at various AT-rich consensus motifs, though independent replication of sequence-specific binding has been limited.
• Chromatin decondensation — Khavinson-group publications describe short-peptide-induced relaxation of chromatin structure, increasing accessibility of transcription-factor binding sites. Mechanism proposed to operate through direct nucleosome interaction rather than through conventional histone-modifying enzymes.
• Hepatic tissue-specificity rationale — Why EDL targets liver and GI rather than other organs is proposed to reflect (a) PEPT1 / PEPT2 expression pattern (particularly high in intestinal and hepatic tissue), (b) tissue-specific chromatin accessibility of Ovagen target genes, and (c) organ-specific expression of downstream effector genes whose regulation is modulated.

What the Research Shows

• Khavinson geroprotector reviews — The Khavinson group has published multiple review articles framing the ultrashort peptide bioregulator family as a "new class of geroprotectors," including Khavinson & Kuznik 2013 (Adv Gerontol; PMID 24003726 — covers the broader bioregulator family including Timalin, Thymogen, Vilon, Epithalamin, Prostatilen, Cortexin, Retinalamin; Ovagen lineage is adjacent).
• Hepatoprotection in carbon tetrachloride / paracetamol models — Russian-language preclinical publications describe Ovagen pretreatment reducing hepatotoxic markers (ALT, AST) and improving liver histology after CCl₄ or acetaminophen challenge in rodents.
• Epigenetic / gene-expression modulation (in vitro) — Cell-culture studies report Ovagen-associated changes in expression of liver-specific and GI-epithelial-specific gene signatures consistent with the tissue-targeting claim.
• Chromatin binding (in vitro) — Older Khavinson-group biophysical work proposes direct peptide–DNA binding at specific sequences; the methodological rigor is variable and not universally accepted.
• POT-family transporter uptake — PEPT1 / PEPT2 mediated cellular uptake of EDL is consistent with the general di/tripeptide transporter biology well-established outside the Khavinson program.
• Immunomodulation / anti-inflammation — Some Khavinson bioregulator review articles propose anti-inflammatory effects across the family; Ovagen-specific anti-inflammation data is modest.
• GI motility / mucosal integrity — Russian clinical reports describe subjective digestive symptom improvement with Ovagen, but these are not controlled RCTs and have not been replicated in Western peer-reviewed literature.
• Adjacent Khavinson peptides (context) — Vesugen (KED) for vessels, Livagen (KEDA) for liver, Testagen (KEDG) for testis, Pinealon (EDR) for nervous system, Epithalon (AEDG) for pineal / telomeres; Ovagen (EDL) sits within this family as the hepato-GI member alongside Livagen.
• No randomized placebo-controlled human trials of Ovagen have been published in peer-reviewed Western journals. Russian clinical-use reports exist but do not meet RCT evidentiary standards.
• Safety signal (Russian experience) — Decades of Russian oral capsule distribution have not surfaced major safety signals, though the evidence quality for safety mirrors the evidence quality for efficacy (predominantly uncontrolled).

Human Data

• No published Western RCTs — PubMed and ClinicalTrials.gov searches as of April 2026 return no randomized placebo-controlled human trials specifically evaluating Ovagen (EDL) for any clinical indication.
• Khavinson group clinical-use reports — Russian clinical-practice reports describe Ovagen use in chronic hepatitis, post-toxic liver recovery, and digestive-function support in aging patients. These reports are observational or open-label, not RCT-level.
• Khavinson geroprotector review (PMID 24003726) — Broader Khavinson-group review of clinical studies of the peptide bioregulator family; Ovagen data is described as part of the family lineage rather than as pivotal trial material.
• Safety experience — Russian OTC capsule product distribution has generated a broad post-marketing experience without major safety signals; counts as decades of informal pharmacovigilance but not a formal safety database.
• Aging / longevity observational claims — Khavinson-group analyses claim reduced mortality and improved organ-specific outcomes in cohorts treated with rotating combinations of bioregulators; Ovagen appears in such cohort analyses as part of hepato-GI rotations.
• Western peer-review status — Ovagen has essentially no peer-reviewed Western-language RCT footprint; the evidence base is structurally limited to the Khavinson ecosystem.

Dosing from the Literature

Ovagen has no validated clinical dose outside the Khavinson-group capsule product distribution. The table summarizes community-use / research-use ranges; these are not regulated or validated.

Reconstitution & Storage

Ovagen is supplied either as oral capsules (finished Russian product) or as a lyophilized research-grade peptide powder for laboratory reconstitution. Oral capsules do not require reconstitution.

• Reconstitution — Add diluent slowly down the side of the vial; swirl gently.
• Storage (lyophilized) — Refrigerated 2–8°C or −20°C; stable 18–24 months.
• Storage (reconstituted) — 2–8°C for 14–28 days with BAC water; aliquot and freeze −80°C for longer storage.
• Oral capsule storage — Cool, dry place; protect from light and moisture per manufacturer instructions.
• Not for clinical sterile compounding — Research-grade reconstitution is not equivalent to pharmaceutical-grade sterile preparation for human injection.

→ Use the Kalios Dosing Calculator for Ovagen reconstitution math

Side Effects & Risks

• Generally well-tolerated (Russian experience) — Decades of oral-capsule consumer use have not surfaced major safety signals. This is informal post-marketing experience rather than a validated safety database.
• GI upset — Occasional mild nausea or stomach discomfort reported with oral administration; usually resolves with continued use.
• Headache — Rarely reported; typically mild.
• Allergic reaction — As with any peptide, hypersensitivity is theoretically possible; rare.
• Injection-site reactions (SubQ research dosing) — Local erythema or discomfort possible; typically self-limiting.
• Hepatic effects — Paradoxically (given the claimed hepatoprotection), chronic high-dose use in patients with active hepatic inflammation should be monitored with LFTs. No specific hepatotoxicity signal has been reported.
• Pregnancy and lactation — Insufficient data; avoid.
• Pediatric use — Not studied; avoid.
• Contraindications (relative) — Active malignancy (theoretical cell-proliferation concern common to multiple bioregulators), pregnancy, lactation, autoimmune disease without clinical supervision.
• Purity concerns — Research-grade peptide purity varies widely by supplier. Third-party testing recommended for any research or extra-label use.
• Product confusion risk — The Russian veterinary "Ovagen" (ovine FSH) is a completely different product — do not confuse with the Khavinson tripeptide. Always verify product identity and labeling.
• Long-term safety — Not formally characterized in any regulated safety database.

Bloodwork & Monitoring

• Comprehensive metabolic panel (CMP) — Baseline liver (AST, ALT, GGT, alkaline phosphatase, bilirubin) and renal function. Repeat every 3–6 months during cyclical use.
• Complete blood count (CBC) — Baseline; annual thereafter.
• Lipid panel — Baseline; relevant for users pursuing broader metabolic / longevity optimization.
• Fasting glucose / HbA1c — Baseline metabolic screening.
• GI symptom log — Bristol stool scale, bloating, abdominal discomfort, appetite — relevant for the digestive-function claim.
• Hepatitis screen if clinically indicated — Viral hepatitis panel if using Ovagen in the context of suspected chronic liver disease; treat underlying disease through validated clinical care.
• Body composition — DEXA optional; relevant for broader longevity-context use.
• Standard reproductive-hormone screening — Not applicable (Ovagen is NOT an ovarian bioregulator despite the name; see What It Is section).
• Not a substitute for clinical hepatology care — Patients with chronic liver disease require validated diagnostic and therapeutic management; Ovagen is not a substitute for this care.

Commonly Stacked With

Khavinson practice uses rotating combinations of bioregulators targeting different organ systems. The following represent typical Khavinson-community pairings.

→ Check compound compatibility in the Stack Builder

Supportive Nutrition & Liver-Health Context

Hepatic health responds more robustly to validated lifestyle and nutritional interventions than to any peptide bioregulator. Users considering Ovagen for liver-support reasons should layer the peptide (if at all) on top of the following established interventions:

• Alcohol reduction or elimination — The single largest hepatoprotective lever available. Chronic alcohol is the most common driver of hepatic injury in most populations; reduction or elimination produces benefit that dwarfs any pharmacologic or peptide intervention.
• Metabolic lifestyle — Weight management, glycemic control, and exercise dramatically reduce MASLD/MASH (metabolic dysfunction-associated steatotic liver disease / steatohepatitis) — the dominant modern liver-disease etiology. Validated evidence base.
• Mediterranean diet pattern — Multiple RCTs and observational studies demonstrate benefit in MASLD, including reduced transaminase elevation and improved histology.
• Coffee (2–4 cups/day) — Robust epidemiologic and mechanistic evidence for hepatoprotection; reduced HCC risk, improved ALT/AST, reduced fibrosis progression.
• N-Acetylcysteine (NAC, 600–1,200 mg) — Glutathione precursor with validated hepatoprotective indication in acetaminophen overdose and supportive evidence in chronic liver disease.
• Silymarin / milk thistle (200–600 mg standardized extract) — Modest evidence in alcohol-related and hepatitis-associated liver disease; part of several hepatic-support regimens.
• Alpha-lipoic acid (300–600 mg) — Mitochondrial antioxidant with supportive evidence in NAFLD.
• Choline (dietary) — Choline deficiency contributes to steatosis; adequate dietary choline (eggs, liver, fish) supports hepatic lipid handling.
• Omega-3 (2–3 g EPA/DHA) — Modest RCT evidence for hepatic steatosis reduction in MASLD.
• Hepatic-stressor avoidance — Minimize non-essential acetaminophen, recreational / unnecessary supplements, and unsupervised exotic herbal preparations of uncertain hepatic-safety profile. Hepatotoxicity from "natural" supplements is a growing clinical problem.
• Vaccination — Hepatitis A and B vaccination; hepatitis C screening and treatment for anyone in the risk-cohort window. Viral hepatitis is treatable / curable with validated therapies (DAAs for HCV).
• Regular hepatic assessment — Annual LFTs, FibroScan or imaging where clinically indicated. Early identification of progressive disease allows validated intervention.

Practical User Notes

• Product identity verification — The name "Ovagen" is shared with a veterinary ovine-FSH product. Always verify the Khavinson hepato-GI tripeptide (EDL, Glu-Asp-Leu) identity on any sourced material before use.
• Source quality matters — Research-grade peptide purity varies widely. For any research use, third-party HPLC and mass-spectrometry identity / purity documentation is the practical floor.
• Don't replace hepatology care with peptides — Anyone with elevated transaminases, known chronic liver disease, suspected cirrhosis, or hepatitis exposure needs validated clinical care — not a research peptide as a substitute.
• Cyclical use pattern — Traditional Khavinson practice is 10–30 day courses with 2–6 month rest intervals. This cycling pattern is community practice rather than RCT-validated.
• Combination rotation — Typical Khavinson users rotate Ovagen with other organ-specific bioregulators (Epithalon for pineal; Pinealon for CNS; Vesugen for vessels; Testagen for testis) as cycling combinations. Again — community practice not RCT evidence.
• Oral vs injectable — Oral capsule is the traditional Russian preparation; subcutaneous research use exists but is not the mainstream practice. Oral bioavailability through POT-family transporters is biophysically plausible.
• Expectation calibration — The size of any effect in a healthy adult is likely small at best. Subjective "energy," "digestion," or "liver feels better" reports are subject to expectancy effects; objective tracking (LFTs, Bristol stool scale, body weight) provides more interpretable data.
• Red flags to stop — New or worsening abdominal symptoms, rising transaminases, jaundice, pruritus, easy bruising, or any new hepatic concern — stop and seek clinical evaluation. Do not assume a research peptide is "helping" without objective confirmation.
• Cancer history consideration — The Khavinson bioregulator family's claim of promoting tissue-specific cell proliferation is a relative contraindication for users with active or recent malignancy; discuss with oncology before use.
• Pregnancy / lactation / pediatrics — Not studied; avoid.
• Stopping — No withdrawal or taper needed. Effects (if any) fade over days to weeks.

Regulatory Status

Related Compounds

Related Khavinson peptides that often come up alongside Ovagen:

Next Steps

Key References

1. Khavinson VKh, Kuznik BI, Ryzhak GA. Peptide bioregulators: the new class of geroprotectors. Message 2. Clinical studies results. Adv Gerontol. 2013;26(1):20-37. PMID: 24003726. (Broader Khavinson-group review of the peptide bioregulator family.)
2. Khavinson VK, Popovich IG, Linkova NS, Mironova ES, Ilina AR. Peptide Regulation of Gene Expression: A Systematic Review. Molecules. 2021;26(22):7053. PMID: 34834147.
3. Khavinson VK. Peptide regulation of aging: 35-year research experience. Bull Exp Biol Med. 2014;157(1):79-82. PMID: 24915933.
4. Khavinson VK, Malinin VV. Gerontological Aspects of Genome Peptide Regulation. Basel: Karger; 2005. ISBN: 978-3-8055-7852-8. (Monograph describing the peptide bioregulator family and proposed intranuclear mechanism.)
5. Khavinson VK. Peptides and Ageing. Neuro Endocrinol Lett. 2002;23 Suppl 3:11-144. PMID: 12374215. (Foundational monograph on the Khavinson peptide bioregulator family.)
6. Anisimov VN, Khavinson VKh. Peptide bioregulation of aging: results and prospects. Biogerontology. 2010;11(2):139-149. PMID: 19609712.
7. Khavinson VK, Soloviev AY, Zhilinskiy DV, Shataeva LK, Bondarev IE. Peptide regulation of gene expression and protein synthesis in bronchial epithelium. Lung. 2014;192(5):781-791. PMID: 25064400.
8. Linkova NS, Polyakova VO, Trofimov AV, Sevostyanova NN, Kvetnoy IM. Peptides as epigenetic regulators: role in aging and diseases. Adv Gerontol. 2012;25(2):215-220. (Khavinson-group perspective on peptide epigenetics.)
9. Khavinson VK, Lin'kova NS, Kvetnoi IM, Kvetnaia TV, Polyakova VO, Korf HW. Molecular cellular mechanisms of peptide regulation of melatonin synthesis in pinealocyte culture. Bull Exp Biol Med. 2012;153(2):255-258. PMID: 22816105.
10. Khavinson V, Ribakova Y, Kulebiakin K, Vladychenskaya E, Kozina L, Arutjunyan A, Boldyrev A. Pinealon increases cell viability by suppression of free radical levels and activating proliferative processes. Rejuvenation Res. 2011;14(5):535-541. PMID: 21978082. (Pinealon — Pinealon EDR is a near-sibling tripeptide illustrating the shared Khavinson mechanism.)
11. Arutjunyan AV, Kozina LS, Stvolinskii SL, Bulygina YR, Mashkina AP, Khavinson VK. Pinealon protects the rat offspring from prenatal hyperhomocysteinemia. Int J Clin Exp Med. 2012;5(2):179-185. PMID: 22567177.
12. Khavinson VKh, Yakovleva NG, Popuchiev VV, Kvetnoi IM, Manokhina RP. Reparative effect of epithalon on ovarian function in old rats. Bull Exp Biol Med. 2001;132(6):1155-1158. PMID: 11875579. (Epithalon work illustrating Khavinson tissue-specific hypothesis; not Ovagen but conceptually adjacent.)
13. Khavinson VK. Tetrapeptide as a geroprotector. Nanotechnol Rev. 2014;3(2):153-165. (Khavinson perspective on short peptide bioregulators.)
14. Chalisova NI, Khavinson VKh. Neuroendocrine regulation of organotypic culture: tropic effect of short peptides. Neurosci Behav Physiol. 2005;35(4):395-401. PMID: 15953974. (Organotypic culture evidence of short peptide tissue-tropic effects.)
15. Khavinson VKh, Ashapkin VV, Vanyushin BF. Short peptides and telomere length regulator drug Epithalon. In: DNA Methylation and Complex Human Disease. Academic Press; 2016:173-188. (Book chapter framing the Khavinson bioregulator hypothesis in the context of epigenetics.)